Vivacit-E Post-market Follow-up Study
← catalyst calendarSponsored by Zimmer Biomet (industry) · ZBH — their whole pipeline →.
Phase
Not applicable
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
258actual
Sites
5
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2013-10-01 | actual | When the study began enrolling |
| Primary completion | 2026-03-02 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-06-30 | estimated | The whole study's end, after follow-up |
| First posted | 2017-07-24 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-01-01 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Osteoarthritis
- Avascular Necrosis of Bone of Hip
- Post-traumatic; Arthrosis
- Congenital Hip Dysplasia
Intervention
- Device: Vivacit-E Liner
Primary outcome
what the primary-completion date above is the date OFSurvival of the study device; whether or not it is still implanted in the subject
measured 10 years
Permalink · ZBH's whole pipeline · Catalyst calendar · Every registered study · What changed